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A B S T R A C T
A pregnant woman with inherited thrombophilia (factor II mutation – 20210A) had two late pregnancy losses. The
first pregnancy was not well documented, but the second pregnancy was complicated by fetal thrombophilia and umbili-
cal artery thrombosis, proven after fetal death. During the third pregnancy enoxaparine was introduced in the therapy
and early amniocentesis was performed. Fetal thrombophilia was proven again. Early delivery was induced and per-
formed with no complications, resulting in a live healthy infant. A history of miscarriages or recurrent fetal loss should
raise suspicion of thrombophilia as a potential cause. It is debatable whether amniocentesis in pursuit of fetal thrombo-
philia should be performed and whether this will lead to a better perinatal outcome. When fetal thrombophilia is diag-
nosed, an earlier induction of delivery should be considered, taking into account the fetal extrauterine viability. The
aforementioned approach of early delivery in cases of inherited fetal thrombophilia could be a possible solution for better
perinatal outcomes.
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Introduction
Fetal inherited thrombophilia is a condition whose
occurrence and risk for a subsequent adverse perinatal
outcome is hard to predict. Thrombosis of the umbilical
artery is a frequent occurrence, and carries a great risk
of perinatal mortality1. In the presence of vessel
thrombosis a higher fetal mortality could be expected.
Although there are reports on umbilical cord thrombosis
and perinatal outcomes, there are no data on the fetal in-
heritance of thrombophilia and its effect on the course of
pregnancy. Moreover, there are no guidelines for the
management of such pregnancies.
Case Report
A thirty-seven-year-old patient with inherited throm-
bophilia (heterozygote for factor II mutation) was ad-
mitted to the hospital for preconception evaluation, due
to the history of two fetal deaths, both in the 38th week of
pregnancy. The past history of the patient was do-
cumented at admittance. Perinatal asphyxia was stated
as the cause of fetal death of the first fetus in 2009. Two
years later, the autopsy of the second fetus showed
thrombosis of umbilical artery, suprarenal glandular
hemorrhage, and pleural and heart ecchymoses. During
the autopsy a skin sample was taken and fetal DNA
isolated from fibroblasts. The DNA analysis revealed an
inherited heterozygous factor II mutation (20210A).
Basic laboratory tests and an ultrasound examination
were performed. Apart from the history of two fetal
deaths, there were no other pathological findings. The
blood tests for thrombophilia from the previous
hospitalization revealed the heterozygous mutation of
factor II (20210A).
One year later the patient came to the hospital re-
porting six weeks and four days of amenorrhea. After
taking blood samples for laboratory tests and a cervical
smear for microbiological tests, clinical and ultrasound
examinations were performed. The concentration of HCG
was 34808 IU/L. The ultrasound examination revealed a
normal pregnancy consistent with the duration of ame-
norrhea (6 weeks and three days). The patient was re-
leased from the hospital to home care with the recom-
mendation of strict rest. Enoxaparine was introduced as
prophylactic therapy for thrombophilia (6000 IU subcu-
1353
Received for publication October 31, 2013
taneous). The patient’s next pregnancy follow up visit
was one month later, and in the 11th week of pregnancy
she was hospitalized again. The ultrasound examination
showed no fetal abnormalities. The patient was advised
to continue with strict rest, and low molecular weight
heparin therapy was continued. During the 21st week of
pregnancy (20 weeks and two days) amniocentesis was
performed with the aim of taking a sample for testing for
thrombophilia. The heterozygous factor II (20210A) mu-
tation was revealed. At the beginning of the 24th week of
pregnancy an oral glucose tolerance test showed no ges-
tational diabetes mellitus (GDM)2. The patient was eva-
luated monthly and the last ultrasound examination
with positive vital fetal signs was performed at full 36
weeks. At that time the ultrasonographically approxi-
mated fetal mass was 2600 g, with cephalic presentation
and no anatomical abnormalities.
The pregnant woman had hereditary thrombophilia,
and two previous fetal deaths. In the last pregnancy the
fetus had the same mutation of factor II like the mother,
and the pregnancy was terminated due to umbilical ar-
tery thrombosis. Considering all the forementioned facts,
we decided to conclude this pregnancy by elective cesa-
rean section, taking into account the fetal extrauterine
viability. In the 37th week of gestation (36 weeks and two
days) a male newborn was delivered, weighing 2640
grams and measuring 46 cm. The Apgar score was 8 and
9 in the 1st and 5th minutes, respectively. The pH of the
umbilical artery was 7.25. The newborn did not need any
care out of the usual, and as the further maternal course
of the puerperium was unremarkable, both mother and
child were discharged from hospital on the 6th post-
operative day. The therapy of enoxaparine was continued
at the same dose for three more weeks.
Discussion
The history of miscarriages or recurrent fetal loss
should raise suspicion of thrombophilia as a potential
cause. Alfirevic et al. described how heterozygous factor
II mutation was associated with intrauterine growth
restriction, and could be found more often in preeclamp-
tic/eclamptic pregnant women3. Although there is no
association with stillbirth according to available litera-
ture, due to our patient’s medical history it seemed
reasonable to perform tests for thrombophilia of the
fetus. The available literature does not present data
about the perinatal outcome in fetuses with inherited
thrombophilia. Several studies have shown that throm-
bosis of the umbilical vein is more common than umbili-
cal artery thrombosis, and its perinatal outcome bet-
ter1,4. In high-risk pregnancies umbilical cord thrombosis
is more frequent with an incidence of about 1/2501,5.
Tests for thrombophilia were not performed in any of the
studies reported.
In one case report of umbilical vein thrombosis with
non-reassuring fetal heart rate and later occurrence of
portal vein thrombosis, tests for thrombophilia were not
performed either. The authors of the case report conclud-
ed that the perinatal outcome would have been worse if
the delivery had not been induced in time6.
Conclusion
It is debatable whether amniocentesis in pursuit of
fetal thrombophilia should be performed and whether
this will lead to a better perinatal outcome. This case
report of two documented fetal deaths, both in the 38th
week of pregnancy, emphasize the importance of early
amniocentesis for diagnosing fetal thrombophilia, espe-
cially in confirmed cases of maternal thrombophilia and
previous fetal thrombophilia and death. When fetal
thrombophilia is diagnosed, an earlier induction of deli-
very should be considered taking into account the fetal
extrauterine viability. The aforementioned approach of
early delivery in cases of inherited fetal thrombophilia
could be a possible solution for better perinatal out-
comes.
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USPJE[NO DOVR[ENJE TRUDNO]E S DJETETOM S NASLJEDNOM TROMBOFILIJOM
NAKON DVIJE FETALNE SMRTI
S A @ E T A K
Trudnica s nasljednom trombofilijom (mutacija ~imbenika II – 20210A) imala je dva gubitka trudno}e u poodmakloj
gestaciji. Tijek prve trudno}e nije detaljno dokumentiran, a druga trudno}a je bila komplicirana trombofilijom fetusa i
trombozom umbilikalne arterije, {to je ustanovljeno nakon smrti fetusa. Tijekom tre}e trudno}e trudnica je lije~ena
enoksaparinom te je u~injena rana amniocenteza. Opet je fetus imao nasljednu trombofiliju. U~injena je prijevremena
indukcija poro|aja bez komplikacija, {to je rezultiralo `ivim i zdravim djetetom. Poba~aji ili ponavljaju}a smrt fetusa
trebala bi pobuditi sumnju na trombofiliju kao mogu}i uzrok. Upitno je je li potrebno izvo|enje amniocenteze sa svr-
hom tra`enja trombofilije u fetusa i utjecanja na bolji perinatalni ishod. U slu~aju prisustva fetalne dijagnoze indukcija
poro|aja prije termina bi se trebala razmotriti, uva`avaju}i sposobnost fetusa za `ivot izvan maternice. Spomenuti
pristup u slu~aju nasljedne fetalne trombofilije bi mogao biti potencijalno rje{enje za bolji perinatalni ishod.
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